NEW YORK – Adaptive Biotechnologies and Microsoft are expanding their existing partnership on mapping adaptive immune responses population-wide to include COVID-19, the companies said on Friday.
Beginning in April, Adaptive will collect de-identified blood samples from patients diagnosed with or recovered from COVID-19. It will sequence the samples and map the immune cell receptor profiles to antigens from SARS-CoV-2, the virus that causes COVID-19. The partners will then upload the immune response signatures to an open-access data portal.